Roche rival has Breakthrough Therapy status.
Activist investor’s intervention adds to buzz surrounding BMS.
Roche’s top seller faces rival four years after patent expiry
Antibody-drug conjugate with FDA gets six-month review.
Mylan and Biocon file biosimilar of white blood cell booster
UK pharma also gets $130m payment from Valeant.
Speculation mounting that Pfizer and others could try for $90 bn plus merger